URGN vs. TERN, RANI, PGEN, NKTX, ATAI, NLTX, SBTX, AVIR, ORGO, and FBLG
Should you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Terns Pharmaceuticals (TERN), Rani Therapeutics (RANI), Precigen (PGEN), Nkarta (NKTX), Atai Life Sciences (ATAI), Neoleukin Therapeutics (NLTX), Silverback Therapeutics (SBTX), Atea Pharmaceuticals (AVIR), Organogenesis (ORGO), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical preparations" industry.
Terns Pharmaceuticals (NASDAQ:TERN) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk.
98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 17.4% of Terns Pharmaceuticals shares are owned by insiders. Comparatively, 11.1% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, UroGen Pharma had 6 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 9 mentions for UroGen Pharma and 3 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.25 beat UroGen Pharma's score of 0.00 indicating that UroGen Pharma is being referred to more favorably in the news media.
UroGen Pharma received 317 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 73.18% of users gave UroGen Pharma an outperform vote while only 59.32% of users gave Terns Pharmaceuticals an outperform vote.
Terns Pharmaceuticals has higher earnings, but lower revenue than UroGen Pharma. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
Terns Pharmaceuticals presently has a consensus target price of $14.94, indicating a potential upside of 146.90%. UroGen Pharma has a consensus target price of $46.67, indicating a potential upside of 251.67%. Given Terns Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe UroGen Pharma is more favorable than Terns Pharmaceuticals.
Terns Pharmaceuticals has a net margin of 0.00% compared to Terns Pharmaceuticals' net margin of -123.61%. Terns Pharmaceuticals' return on equity of 0.00% beat UroGen Pharma's return on equity.
Terns Pharmaceuticals has a beta of -0.49, suggesting that its stock price is 149% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
Summary
UroGen Pharma beats Terns Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get UroGen Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
UroGen Pharma Competitors List
Related Companies and Tools
